Lunai Bioworks (LNAI) Stock Price, News & Analysis

Company Overview

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

Key Stats

• Today's Range: $1.13 to $1.20
• 50-Day Range: $1.14 to $2.61
• 52-Week Range: $1.13 to $13.28
• Volume: 15,417 shs
• Average Volume: 1.21 million shs
• Market Capitalization: $5.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Lunai Bioworks Stock Analysis - MarketRank™

Lunai Bioworks scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Lunai Bioworks has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Lunai Bioworks has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lunai Bioworks is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lunai Bioworks is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.96% of the float of Lunai Bioworks has been sold short.

Short Interest Ratio / Days to Cover

Lunai Bioworks has a short interest ratio ("days to cover") of 3.88, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lunai Bioworks has recently decreased by 23.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lunai Bioworks does not currently pay a dividend.

Dividend Growth

Lunai Bioworks does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lunai Bioworks insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.50% of the stock of Lunai Bioworks is held by insiders.

Percentage Held by Institutions

71.41% of the stock of Lunai Bioworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 2/17/2026
• Today: 10/06/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LNAI
• CIK: 1527728
• Web: www.renovarogroup.com
• Phone: (453) 917-9840
• Fax: N/A
• Employees: 29
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$178.01 million
• Net Margins: N/A
• Pretax Margin: -610,877.00%
• Return on Equity: N/A
• Return on Assets: -1,617.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.19
• Quick Ratio: 0.19

Sales & Book Value

• Annual Sales: $20.94 thousand
• Price / Sales: 247.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($9.92) per share
• Price / Book: -0.12

Miscellaneous

• Outstanding Shares: 4,534,000
• Free Float: 4,511,000
• Market Cap: $5.19 million
• Optionable: N/A
• Beta: 0.37